Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,068
datasets available to search
ShareScore release 0.9.0
Dataset results
1,068 results for “PD-1”
Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer
ClinicalTrials.gov study NCT02500121. IPD Sharing: NO. Countries: 1. Publications: 1.
Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC)
ClinicalTrials.gov study NCT05061017. IPD Sharing: NO. Countries: 1. Publications: 1.
Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy
ClinicalTrials.gov study NCT02731729. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Study Investigating Safety, Tolerability, Pharmacokinetics (PK) and Antitumor Activities of Anti-PD-1 (Programmed Death-1) Monoclonal Antibody
ClinicalTrials.gov study NCT04068519. IPD Sharing: YES. Countries: 1. Publications: 2.
PD-1 Inhibition to Determine CNS Reservoir of HIV-Infection
ClinicalTrials.gov study NCT03239899. IPD Sharing: YES. Countries: 1. Publications: 1.
PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy
ClinicalTrials.gov study NCT03132636. IPD Sharing: Not stated. Countries: 10. Publications: 5.
Study of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Participants With Advanced Solid Tumors
ClinicalTrials.gov study NCT03250832. IPD Sharing: NO. Countries: 2. Publications: 1.
Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced Malignancies
ClinicalTrials.gov study NCT04181788. IPD Sharing: YES. Countries: 6. Publications: 1.
PD-1 Knockout Engineered T Cells for Metastatic Non-small Cell Lung Cancer
ClinicalTrials.gov study NCT02793856. IPD Sharing: UNDECIDED. Countries: 1. Publications: 8.
Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) for Advanced Melanoma in Anti-Programmed Death-1/Programmed Death-Ligand 1 (PD-1/L1)-Exposed Participants (MK-7902-004/E7
ClinicalTrials.gov study NCT03776136. IPD Sharing: YES. Countries: 5. Publications: 1.
Neoadjuvant Anti PD-1 Immunotherapy in Resectable Non-small Cell Lung Cancer
ClinicalTrials.gov study NCT03197467. IPD Sharing: NO. Countries: 1. Publications: 3.
NET-PD LS-1 Creatine in Parkinson's Disease
ClinicalTrials.gov study NCT00449865. IPD Sharing: Not stated. Countries: 2. Publications: 5.
PD-1 Inhibition in Advanced Myeloproliferative Neoplasms
ClinicalTrials.gov study NCT03065400. IPD Sharing: NO. Countries: 1. Publications: 1.
A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors
ClinicalTrials.gov study NCT03708328. IPD Sharing: NO. Countries: 6. Publications: 0.
Presence of tertiary lymphoid structures and exhausted tissue-resident T cells determines clinical response to PD-1 blockade in renal cell carcinoma
Open the record for dataset details and reuse information.
CTLA-4 and PD-1 expressed in EMT6 mouse mammary carcinoma cell line acquired radio-resistance to gamma-ray irradiation.
<p>Supplementary File of manuscript entitled CTLA-4 and PD-1 expressed in EMT6 mouse mammary carcinoma cell line acquired radio-resistance to gamma-ray irradiation.</p>
Immunotherapy-mediated thyroid dysfunction: genetic risk and impact on outcomes with PD-1 blockade in non-small cell lung cancer
<p>Polygenic risk score weights derived using LDpred for hypothyroidism and thyroid medication use.</p>
Deep learning to estimate durable clinical benefit and prognosis from patients with non-small cell lung cancer treated with PD-1/PD-L1 blockade
<p>Different biomarkers based on genomics variants have been used to predict the response of patients treated with PD-1/programmed death receptor 1 ligand (PD-L1) blockade. We aimed to use deep-learning algorithm to estimate clinical benefit in patients with non-small-cell lung cancer (NSCLC) before immunotherapy. Peripheral blood samples or tumor tissues of 915 patients from three independent centers were profiled by whole-exome sequencing or next-generation sequencing. Based on convolutional neural network (CNN) and three conventional machine learning (cML) methods, we used multi-panels to train the models for predicting the durable clinical benefit (DCB) and combined them to develop a nomogram model for predicting prognosis. In the three cohorts, the CNN achieved the highest area under the curve of predicting DCB among cML, PD-L1 expression, and tumor mutational burden (area under the curve [AUC] = 0.965, 95% confidence interval [CI]: 0.949–0.978, <em>P</em> < 0.001; AUC =0.965, 95% CI: 0.940–0.989, <em>P</em> < 0.001; AUC = 0.959, 95% CI: 0.942–0.976, <em>P</em> < 0.001, respectively). Patients with CNN-high had longer progression-free survival (PFS) and overall survival (OS) than patients with CNN-low in the three cohorts. Subgroup analysis confirmed the efficient predictive ability of CNN. Combining three cML methods (CNN, SVM, and RF) yielded a robust comprehensive nomogram for predicting PFS and OS in the three cohorts (each <em>P</em> < 0.001). The proposed deep-learning method based on mutational genes revealed the potential value of clinical benefit prediction in patients with NSCLC and provides novel insights for combined machine learning in PD-1/PD-L1 blockade.</p>
Supplementary data for "Engineering PD-1-targeted small protein variants for in vitro diagnostics and in vivo PET imaging"
<p>Supplementary data for "Engineering PD-1-targeted small protein variants for in vitro diagnostics and in vivo PET imaging". The docking.zip file contains ClusPro protein/protein docking results for all binding protein variants using either murine PD-1 structure (3bikB) or human PD-1 AF2 model as receptors. The pymol session contains data and scenes used to generate the Figures in the paper.</p>
Isunakinra Alone and in Combination With a PD-1/PD-L1 Inhibitor in Patients With Solid Tumors
ClinicalTrials.gov study NCT04121442. IPD Sharing: Not stated. Countries: 1. Publications: 2.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.